{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T04:42:11Z","timestamp":1768452131927,"version":"3.49.0"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004083","name":"Ministry of Science ICT and Future Planning","doi-asserted-by":"publisher","award":["2017M3A9C8060403"],"award-info":[{"award-number":["2017M3A9C8060403"]}],"id":[{"id":"10.13039\/501100004083","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014188","name":"Korea Ministry of Science and ICT","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.bcp.2021.114658","type":"journal-article","created":{"date-parts":[[2021,6,17]],"date-time":"2021-06-17T00:53:50Z","timestamp":1623891230000},"page":"114658","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells"],"prefix":"10.1016","volume":"190","author":[{"given":"Ji-Hea","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Jin","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ka-Won","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Hyun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Soo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2021.114658_b0005","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.bcp.2021.114658_b0010","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s13238-010-0016-z","article-title":"Molecular and cellular bases of chronic myeloid leukemia","volume":"1","author":"Chen","year":"2010","journal-title":"Protein Cell"},{"key":"10.1016\/j.bcp.2021.114658_b0015","first-page":"1553","article-title":"Activation of tyrosinase kinase and microfilament-binding functions of c-abl by bcr sequences in bcr\/abl fusion proteins","volume":"11","author":"McWhirter","year":"1991","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.bcp.2021.114658_b0020","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/leu.2011.325","article-title":"Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitors","volume":"26","author":"Traer","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2021.114658_b0025","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1074\/jbc.M111501200","article-title":"Functional cooperation among Ras, STAT5, and phosphatidylinositol 3-kinase is required for full oncogenic activities of BCR\/ABL in K562 cells","volume":"277","author":"Sonoyama","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114658_b0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0145-2126(00)00010-2","article-title":"The inhibition of ERK\/MAPK not the activation of JNK\/SAPK is primarily required to induce apoptosis in chronic myelogenous leukemic K562 cells","volume":"24","author":"Kang","year":"2000","journal-title":"Leuk. Res."},{"key":"10.1016\/j.bcp.2021.114658_b0035","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/1878-0261.12186","article-title":"Overexpression of Tpl2 is linked to imatinib resistance and activation of MEK-ERK and NF-\u03baB pathways in a model of chronic myeloid leukemia","volume":"12","author":"Chorzalska","year":"2018","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2021.114658_b0040","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1007\/s00018-015-1867-5","article-title":"Targeting PI3K\/AKT\/mTOR network for treatment of leukemia","volume":"72","author":"Bertacchini","year":"2015","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.bcp.2021.114658_b0045","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ebiom.2019.05.003","article-title":"A miR-567-PIK3AP1-PI3K\/AKT-c-Myc feedback loop regulates tumour growth and chemoresistance in gastric cancer","volume":"44","author":"Zhang","year":"2019","journal-title":"EBioMedicine."},{"key":"10.1016\/j.bcp.2021.114658_b0050","doi-asserted-by":"crossref","unstructured":"L. Yang, P. Shi, G. Zhao, J. Xu, W. Peng, J. Zhang, G. Zhang, X. Wang, Z. Dong, F. Chen, H. Cui, Targeting cancer stem cell pathways for cancer therapy, Springer US, 2020. doi: 10.1038\/s41392-020-0110-5.","DOI":"10.1038\/s41392-020-0110-5"},{"key":"10.1016\/j.bcp.2021.114658_b0055","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1158\/1078-0432.CCR-06-1516","article-title":"Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA working party on chronic myeloid leukemia","volume":"12","author":"Soverini","year":"2006","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.bcp.2021.114658_b0060","doi-asserted-by":"crossref","first-page":"5148","DOI":"10.1074\/jbc.M209861200","article-title":"A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571","volume":"278","author":"B\u00f6hmer","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114658_b0065","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcp.2021.114658_b0070","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1182\/blood-2006-02-004580","article-title":"Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: High efficacy of drug combinations","volume":"108","author":"Bradeen","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114658_b0075","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O\u2019Hare","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114658_b0080","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1200\/JCO.2009.21.8230","article-title":"Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase","volume":"27","author":"Hughes","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.bcp.2021.114658_b0085","doi-asserted-by":"crossref","unstructured":"A.S. Corbin, A. Agarwal, M. Loriaux, J. Cortes, M.W. Deininger, B.J. Druker, Erratum: Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity (Journal of Clinical Investigation (2011) 121, 1, (396-409) DOI: 10.1172\/JCI35721), J. Clin. Invest. 121 (2011) 1222. doi: 10.1172\/JCI46407.","DOI":"10.1172\/JCI35721"},{"key":"10.1016\/j.bcp.2021.114658_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-018-0805-1","article-title":"Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia","volume":"17","author":"Massimino","year":"2018","journal-title":"Mol. Cancer."},{"key":"10.1016\/j.bcp.2021.114658_b0095","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2017.09.030","article-title":"CXCR2 promotes breast cancer metastasis and chemoresistance via suppression of AKT1 and activation of COX2","volume":"412","author":"Xu","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2021.114658_b0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-015-1793-9","article-title":"The prognostic value of CXC-chemokine receptor 2 (CXCR2) in gastric cancer patients","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2021.114658_b0105","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/bjc.2012.177","article-title":"Interleukin-8 and its receptor CXCR2 in the tumour microenvironment promote colon cancer growth, progression and metastasis","volume":"106","author":"Lee","year":"2012","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.bcp.2021.114658_b0110","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1517\/14728221003652471","article-title":"Targeting CXCR1\/CXCR2 receptor antagonism in malignant melanoma","volume":"14","author":"Sharma","year":"2010","journal-title":"Expert Opin. Ther. Targets."},{"key":"10.1016\/j.bcp.2021.114658_b0115","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.ccell.2016.04.014","article-title":"CXCR2 inhibition profoundly suppresses metastases and augments immunotherapy in pancreatic ductal adenocarcinoma","volume":"29","author":"Steele","year":"2016","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2021.114658_b0120","doi-asserted-by":"crossref","unstructured":"Y. Li, Y. He, W. Butler, L. Xu, Y. Chang, K. Lei, H. Zhang, Y. Zhou, A.C. Gao, Q. Zhang, D.G. Taylor, D. Cheng, S. Farber-Katz, R. Karam, T. Landrith, B. Li, S. Wu, V. Hsuan, Q. Yang, H. Hu, X. Chen, M. Flowers, S.J. Mccall, J.K. Lee, B.A. Smith, J.W. Park, A.S. Goldstein, O.N. Witte, Q. Wang, M.B. Rettig, A.J. Armstrong, Q. Cheng, J. Huang, Targeting cellular heterogeneity with CXCR2 blockade for the treatment of therapy-resistant prostate cancer, 2019. http:\/\/stm.sciencemag.org\/.","DOI":"10.1126\/scitranslmed.aax0428"},{"key":"10.1016\/j.bcp.2021.114658_b0125","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.ccr.2012.11.012","article-title":"Chemokine to the Rescue: Interleukin-8 Mediates Resistance to PI3K-Pathway-Targeted Therapy in Breast Cancer","volume":"22","author":"Abraham","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bcp.2021.114658_b0130","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.cyto.2011.06.005","article-title":"Autocrine production of interleukin-8 confers cisplatin and paclitaxel resistance in ovarian cancer cells","volume":"56","author":"Wang","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.bcp.2021.114658_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/srep18411","article-title":"IL-8 as mediator in the microenvironment-leukaemia network in acute myeloid leukaemia","volume":"5","author":"Kuett","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2021.114658_b0140","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1182\/blood-2015-01-621631","article-title":"IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells","volume":"125","author":"Schinke","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114658_b0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-020-07102-x","article-title":"Etoposide-mediated interleukin-8 secretion from bone marrow stromal cells induces hematopoietic stem cell mobilization","volume":"20","author":"Kang","year":"2020","journal-title":"BMC Cancer"},{"key":"10.1016\/j.bcp.2021.114658_b0150","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1182\/blood-2015-08-661785","article-title":"CXCR2 and CXCL4 regulate survival and self-renewal of hematopoietic stem\/progenitor cells","volume":"128","author":"Sinclair","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bcp.2021.114658_b0155","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/scd.2019.0188","article-title":"CXCR2 ligands and mTOR activation enhance reprogramming of human somatic cells to pluripotent stem cells","volume":"29","author":"Lee","year":"2020","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bcp.2021.114658_b0160","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1089\/scd.2015.0395","article-title":"CXCR2 Inhibition in human pluripotent stem cells induces predominant differentiation to mesoderm and endoderm through repression of mTOR, \u03b2-catenin, and hTERT activities","volume":"25","author":"Jung","year":"2016","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.bcp.2021.114658_b0165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0134783","article-title":"SB225002 induces cell death and cell cycle arrest in acute lymphoblastic leukemia cells through the activation of GLIPR1","volume":"10","author":"De Vasconcellos","year":"2015","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114658_b0170","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-13-0410","article-title":"Combination of imatinib with CXCR4 Antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo","volume":"13","author":"Beider","year":"2014","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2021.114658_b0175","doi-asserted-by":"crossref","first-page":"12128","DOI":"10.18632\/oncotarget.3665","article-title":"Discovery of a small molecule targeting SET-PP2A interaction to overcome BCR-ABLT315I mutation of chronic myeloid leukemia","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.bcp.2021.114658_b0180","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41422-018-0097-4","article-title":"A dynamic N 6-methyladenosine methylome regulates intrinsic and acquired resistance to tyrosine kinase inhibitors","volume":"28","author":"Yan","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.bcp.2021.114658_b0185","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1093\/bioinformatics\/btt314","article-title":"Isaac: ultra-fast whole-genome secondary analysis on Illumina sequencing platforms","volume":"29","author":"Raczy","year":"2013","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bcp.2021.114658_b0190","doi-asserted-by":"crossref","unstructured":"B.S. Agrovskii, V.V. Vorob\u2019ev, A.S. Gurvich, V.V. Pokasov, A.N. Ushakov, Intensity Fluctuations of Pulsed Laser Radiation During Thermal Self-Interaction in a Turbulent Medium., Sov. J. Quantum Electron. 10 (1980) 308\u2013312. doi: 10.1070\/qe1980v010n03abeh009978.","DOI":"10.1070\/QE1980v010n03ABEH009978"},{"key":"10.1016\/j.bcp.2021.114658_b0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2012.00035","article-title":"Using Drosophila melanogaster as a model for genotoxic chemical mutational studies with a new program, SnpSift","volume":"3","author":"Cingolani","year":"2012","journal-title":"Front. Genet."},{"key":"10.1016\/j.bcp.2021.114658_b0200","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/nar\/gkt1113","article-title":"ClinVar: public archive of relationships among sequence variation and human phenotype","volume":"42","author":"Landrum","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2021.114658_b0205","doi-asserted-by":"crossref","first-page":"D840","DOI":"10.1093\/nar\/gkw971","article-title":"The ExAC browser: displaying reference data information from over 60 000 exomes","volume":"45","author":"Karczewski","year":"2017","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.bcp.2021.114658_b0210","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1093\/bioinformatics\/btp352","article-title":"The sequence alignment\/map format and SAMtools","volume":"25","author":"Li","year":"2009","journal-title":"Bioinformatics"},{"key":"10.1016\/j.bcp.2021.114658_b0215","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0083510","article-title":"Inhibition of PI3K\/mTOR overcomes nilotinib resistance in BCR-ABL1 positive leukemia cells through translational down-regulation of MDM2","volume":"8","author":"Ding","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.bcp.2021.114658_b0220","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1158\/1535-7163.MCT-19-0051","article-title":"Morin inhibits proliferation and induces apoptosis by modulating the MIR-188-5p\/PTEN\/Akt regulatory pathway in CML cells","volume":"18","author":"Nie","year":"2019","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2021.114658_b0225","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/0092-8674(92)90241-4","article-title":"Dominant negative MYC blocks transformation by ABL oncogenes","volume":"70","author":"Sawyers","year":"1992","journal-title":"Cell"},{"key":"10.1016\/j.bcp.2021.114658_b0230","doi-asserted-by":"crossref","unstructured":"G. Nestal de Moraes, P.S. Souza, F.C. de F. Costas, F.C. Vasconcelos, F.R.S. Reis, R.C. Maia, The Interface between BCR-ABL-Dependent and -Independent Resistance Signaling Pathways in Chronic Myeloid Leukemia, Leuk. Res. Treatment. 2012 (2012) 1\u201319. doi: 10.1155\/2012\/671702.","DOI":"10.1155\/2012\/671702"},{"key":"10.1016\/j.bcp.2021.114658_b0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3009073","article-title":"A therapeutically targetable mechanism of BCR-ABL \u2013 independent imatinib resistance in chronic myeloid leukemia","volume":"6","author":"Ma","year":"2014","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.bcp.2021.114658_b0240","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1038\/leusup.2014.3","article-title":"STAT3 as a mediator of BCR-ABL1-independent resistance in chronic myeloid leukemia","volume":"3","author":"Eiring","year":"2014","journal-title":"Leuk. Suppl."},{"key":"10.1016\/j.bcp.2021.114658_b0245","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2021.114658_b0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3324\/haematol.2019.234898","article-title":"Defining niche interactions to target chronic myeloid leukemia stem cells","volume":"105","author":"Mitchell","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.bcp.2021.114658_b0255","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","article-title":"Chronic myeloid leukemia stem cells","volume":"33","author":"Houshmand","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.bcp.2021.114658_b0260","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.molonc.2008.07.003","article-title":"The chemokine interleukin-8 and the surface activation protein CD69 are markers for Bcr-Abl activity in chronic myeloid leukemia","volume":"2","author":"Hantschel","year":"2008","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.bcp.2021.114658_b0265","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/nature18288","article-title":"Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells","volume":"534","author":"Abraham","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.bcp.2021.114658_b0270","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1158\/1541-7786.MCR-10-0356","article-title":"MYC in chronic myeloid leukemia: Induction of aberrant DNA synthesis and association with poor response to imatinib","volume":"9","author":"Albajar","year":"2011","journal-title":"Mol. Cancer Res."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221002719?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295221002719?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T13:29:27Z","timestamp":1757770167000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295221002719"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":54,"alternative-id":["S0006295221002719"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114658","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CXCR2, a novel target to overcome tyrosine kinase inhibitor resistance in chronic myelogenous leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2021.114658","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114658"}}